Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia
Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-...
Gespeichert in:
| Veröffentlicht in: | Retina (Philadelphia, Pa.) Jg. 29; H. 8; S. 1062 |
|---|---|
| 1. Verfasser: | |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
United States
01.09.2009
|
| Schlagworte: | |
| ISSN: | 1539-2864, 1539-2864 |
| Online-Zugang: | Weitere Angaben |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-term effectiveness has been disappointing. Antivascular endothelial growth factor (anti-VEGF) drugs are now widely used not only to treat choroidal neovascularization in AMD but also for choroidal neovascularization in other conditions. This review summarizes the data supplied by published case series studies about anti-VEGF therapy in mCNV.
Analysis of the current literature allowed discussion of the optimal parameters for mCNV treatment by anti-VEGF, including the choice of anti-VEGF drug, its dose, the treatment protocol, and indications for retreatment.
To date, the results of intravitreal bevacizumab or ranibizumab for mCNV have been reported in at least 14 studies, but they were all pilot, monocentric, and noncomparative case series. Nevertheless, they provided useful information on >250 patients and showed similar results, with significant improvement of visual acuity and an excellent safety profile.
Shifting from one treatment to another is always difficult in the absence of prospective and controlled comparative studies. However, in 2009, intravitreal ranibizumab or bevacizumab may be considered as first-line therapy for sub- and juxtafoveal mCNV for three reasons: the safety of anti-VEGF drugs and intravitreal injection procedures; the disappointing long-term results of other therapies, including verteporfin treatment; and the excellent convergent results of anti-VEGF therapy in all pilot studies. |
|---|---|
| AbstractList | Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-term effectiveness has been disappointing. Antivascular endothelial growth factor (anti-VEGF) drugs are now widely used not only to treat choroidal neovascularization in AMD but also for choroidal neovascularization in other conditions. This review summarizes the data supplied by published case series studies about anti-VEGF therapy in mCNV.
Analysis of the current literature allowed discussion of the optimal parameters for mCNV treatment by anti-VEGF, including the choice of anti-VEGF drug, its dose, the treatment protocol, and indications for retreatment.
To date, the results of intravitreal bevacizumab or ranibizumab for mCNV have been reported in at least 14 studies, but they were all pilot, monocentric, and noncomparative case series. Nevertheless, they provided useful information on >250 patients and showed similar results, with significant improvement of visual acuity and an excellent safety profile.
Shifting from one treatment to another is always difficult in the absence of prospective and controlled comparative studies. However, in 2009, intravitreal ranibizumab or bevacizumab may be considered as first-line therapy for sub- and juxtafoveal mCNV for three reasons: the safety of anti-VEGF drugs and intravitreal injection procedures; the disappointing long-term results of other therapies, including verteporfin treatment; and the excellent convergent results of anti-VEGF therapy in all pilot studies. Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-term effectiveness has been disappointing. Antivascular endothelial growth factor (anti-VEGF) drugs are now widely used not only to treat choroidal neovascularization in AMD but also for choroidal neovascularization in other conditions. This review summarizes the data supplied by published case series studies about anti-VEGF therapy in mCNV.BACKGROUNDPathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger than 50 years. The current treatment of subfoveal myopic choroidal neovascularization (mCNV) is verteporfin photodynamic therapy, but its long-term effectiveness has been disappointing. Antivascular endothelial growth factor (anti-VEGF) drugs are now widely used not only to treat choroidal neovascularization in AMD but also for choroidal neovascularization in other conditions. This review summarizes the data supplied by published case series studies about anti-VEGF therapy in mCNV.Analysis of the current literature allowed discussion of the optimal parameters for mCNV treatment by anti-VEGF, including the choice of anti-VEGF drug, its dose, the treatment protocol, and indications for retreatment.METHODSAnalysis of the current literature allowed discussion of the optimal parameters for mCNV treatment by anti-VEGF, including the choice of anti-VEGF drug, its dose, the treatment protocol, and indications for retreatment.To date, the results of intravitreal bevacizumab or ranibizumab for mCNV have been reported in at least 14 studies, but they were all pilot, monocentric, and noncomparative case series. Nevertheless, they provided useful information on >250 patients and showed similar results, with significant improvement of visual acuity and an excellent safety profile.RESULTSTo date, the results of intravitreal bevacizumab or ranibizumab for mCNV have been reported in at least 14 studies, but they were all pilot, monocentric, and noncomparative case series. Nevertheless, they provided useful information on >250 patients and showed similar results, with significant improvement of visual acuity and an excellent safety profile.Shifting from one treatment to another is always difficult in the absence of prospective and controlled comparative studies. However, in 2009, intravitreal ranibizumab or bevacizumab may be considered as first-line therapy for sub- and juxtafoveal mCNV for three reasons: the safety of anti-VEGF drugs and intravitreal injection procedures; the disappointing long-term results of other therapies, including verteporfin treatment; and the excellent convergent results of anti-VEGF therapy in all pilot studies.CONCLUSIONShifting from one treatment to another is always difficult in the absence of prospective and controlled comparative studies. However, in 2009, intravitreal ranibizumab or bevacizumab may be considered as first-line therapy for sub- and juxtafoveal mCNV for three reasons: the safety of anti-VEGF drugs and intravitreal injection procedures; the disappointing long-term results of other therapies, including verteporfin treatment; and the excellent convergent results of anti-VEGF therapy in all pilot studies. |
| Author | Cohen, Salomon Y |
| Author_xml | – sequence: 1 givenname: Salomon Y surname: Cohen fullname: Cohen, Salomon Y email: sycohen@club-internet.fr organization: Centre Ophtalmologique d'Imagerie et de Laser, Paris, France. sycohen@club-internet.fr |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/19734760$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkF1LwzAYhYNM3If-A5HcedWZrzbp5RjbHAy8UW9LkiZbJG1q0grz11tRwatzODwc3vfMwaQNrQHgFqMlRiV_2K82S6QQpoZigRVWCssLMMM5LTMiCjb556dgntIbQjgXIr8CU1xyyniBZqBetb3LXje7LazjcExQJtifDCQIldC6mPrMu9Z8Z1F2Z2hDhPoUYnC19LA14UMmPXgZ3afsXWiha2En-1Pw4eg0bM6hc_IaXFrpk7n51QV42W6e14_Z4Wm3X68Omaac9FlBqEXMaMwZxUyxnFNCEFPIcitqwrgwBaMCMVYWopTKMqK0ZtaMnLSkJgtw_9PbxfA-mNRXjUvaeC_HQ4dUjU8jWhZFPpJ3v-SgGlNXXXSNjOfqbxjyBU07aDE |
| CitedBy_id | crossref_primary_10_1016_j_ijbiomac_2018_06_105 crossref_primary_10_1038_eye_2012_97 crossref_primary_10_1097_MD_0000000000014905 crossref_primary_10_1159_000512635 crossref_primary_10_1007_s00417_011_1889_0 crossref_primary_10_1097_IAE_0b013e31821ba2dc crossref_primary_10_1016_j_ajo_2013_04_040 crossref_primary_10_1371_journal_pone_0271342 crossref_primary_10_1016_j_tjo_2016_05_007 crossref_primary_10_1038_s41598_023_32417_7 crossref_primary_10_1097_IAE_0b013e3181e096f3 crossref_primary_10_3390_ph16040494 crossref_primary_10_1016_j_cellsig_2013_03_017 crossref_primary_10_3892_etm_2023_12000 crossref_primary_10_1159_000351660 crossref_primary_10_1016_S0140_6736_12_60272_4 crossref_primary_10_1016_j_jchromb_2016_05_045 crossref_primary_10_1016_j_sjopt_2014_09_004 crossref_primary_10_1159_000529342 crossref_primary_10_1007_s00347_014_3035_y crossref_primary_10_1016_j_ajo_2015_07_004 crossref_primary_10_1111_aos_12457 crossref_primary_10_1089_jop_2014_0033 crossref_primary_10_1007_s00417_009_1232_1 crossref_primary_10_1007_s10384_012_0160_5 crossref_primary_10_1038_eye_2010_226 crossref_primary_10_1097_IAE_0000000000000684 crossref_primary_10_1097_IAE_0b013e318261a73c crossref_primary_10_1038_eye_2013_8 crossref_primary_10_1136_bmjophth_2023_001396 crossref_primary_10_1007_s00417_016_3396_9 crossref_primary_10_3389_fpubh_2022_846601 crossref_primary_10_1080_02713683_2020_1742357 crossref_primary_10_1097_IAE_0b013e3182681066 crossref_primary_10_1007_s00417_014_2721_4 crossref_primary_10_1074_jbc_M111_226266 crossref_primary_10_1177_112067211002000425 crossref_primary_10_1007_BF03256411 crossref_primary_10_1038_eye_2012_75 crossref_primary_10_1089_jop_2011_0106 crossref_primary_10_1016_j_ophtha_2013_06_043 crossref_primary_10_1007_s10792_013_9761_3 crossref_primary_10_3341_kjo_2011_25_3_161 crossref_primary_10_1007_s00417_013_2282_y crossref_primary_10_1016_j_patcog_2024_110757 crossref_primary_10_1007_s10792_022_02261_1 crossref_primary_10_1111_j_1442_9071_2011_02684_x crossref_primary_10_1007_s10384_016_0496_3 crossref_primary_10_1089_jop_2012_0067 crossref_primary_10_3390_ijms160819796 crossref_primary_10_3928_23258160_20181002_05 crossref_primary_10_3390_ph14101042 crossref_primary_10_1007_s00417_014_2886_x crossref_primary_10_1080_02713683_2020_1781193 crossref_primary_10_1016_j_ophtha_2017_04_028 crossref_primary_10_1016_j_survophthal_2014_10_002 crossref_primary_10_1007_s10384_014_0363_z crossref_primary_10_1097_IAE_0000000000000610 crossref_primary_10_1016_j_pharma_2012_03_006 crossref_primary_10_1016_j_xops_2025_100834 crossref_primary_10_1038_s41598_018_33926_6 crossref_primary_10_1016_j_gene_2021_145573 crossref_primary_10_1097_IAE_0b013e318227aa09 crossref_primary_10_1097_IAE_0b013e31826956e4 crossref_primary_10_1097_IAE_0b013e31827d260a |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/IAE.0b013e3181b1bb1a |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1539-2864 |
| ExternalDocumentID | 19734760 |
| Genre | Journal Article Review |
| GroupedDBID | --- .-D .GJ .Z2 01R 0R~ 123 1J1 2V- 40H 53G 5VS 71W 77Y 7O~ AAAAV AAAXR AAGIX AAHPQ AAIQE AAMOA AAMTA AAQKA AAQQT AARTV AASCR AASOK AAXQO AAYEP ABASU ABBUW ABDIG ABJNI ABOCM ABPXF ABVCZ ABXRP ABXVJ ABZAD ABZZY ACCJW ACDDN ACEWG ACGFS ACILI ACLDA ACWDW ACWRI ACXJB ACXNZ ACZKN ADFPA ADGGA ADHPY ADNKB AE3 AE6 AEETU AFBFQ AFDTB AFFNX AFMFY AFUWQ AGINI AHOMT AHPAA AHQNM AHVBC AIJEX AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AOQMC BOYCO BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DUNZO E.X EBS ECM EEVPB EIF EJD ERAAH EX3 F2K F2L F2M F2N F5P FCALG FL- FW0 GNXGY GQDEL H0~ HLJTE HZ~ IKREB IKYAY IN~ IPNFZ JK3 JK8 K8S KD2 KMI L-C N9A NPM N~7 N~B N~M O9- OCUKA ODA OL1 OLG OLH OLU OLV OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OXXIT P-K R58 RIG RLZ S4R S4S ST3 TEORI TSPGW V2I W3M WOQ WOW X3V X3W YFH ZFV ZGI ZZMQN 7X8 ADKSD |
| ID | FETCH-LOGICAL-c372t-623f04ec174314b45732204b0f7f8d2478e64380449689abf42bcc4fe732af2d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 94 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000270051800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1539-2864 |
| IngestDate | Sun Sep 28 11:22:49 EDT 2025 Mon Jul 21 05:18:47 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 8 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c372t-623f04ec174314b45732204b0f7f8d2478e64380449689abf42bcc4fe732af2d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 19734760 |
| PQID | 734039665 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_734039665 pubmed_primary_19734760 |
| PublicationCentury | 2000 |
| PublicationDate | 2009-Sep 20090901 |
| PublicationDateYYYYMMDD | 2009-09-01 |
| PublicationDate_xml | – month: 09 year: 2009 text: 2009-Sep |
| PublicationDecade | 2000 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Retina (Philadelphia, Pa.) |
| PublicationTitleAlternate | Retina |
| PublicationYear | 2009 |
| SSID | ssj0015885 |
| Score | 2.248575 |
| SecondaryResourceType | review_article |
| Snippet | Pathologic myopia is the second cause of choroidal neovascularization, after age-related macular degeneration (AMD), and the first cause in patients younger... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1062 |
| SubjectTerms | Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - adverse effects Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized Bevacizumab Choroidal Neovascularization - drug therapy Choroidal Neovascularization - etiology Humans Myopia, Degenerative - complications Myopia, Degenerative - drug therapy Ranibizumab Treatment Outcome Vascular Endothelial Growth Factor A - antagonists & inhibitors Visual Acuity - drug effects |
| Title | Anti-VEGF drugs as the 2009 first-line therapy for choroidal neovascularization in pathologic myopia |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/19734760 https://www.proquest.com/docview/734039665 |
| Volume | 29 |
| WOSCitedRecordID | wos000270051800002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1Fe8sBqNbGd2JlQhVpgaNUBULfKjm2UgaQ0LVL_PeckbSfEwJIlD1n23eU7f3f-ELqXCnCoc4xoRjUB_M-JjCBrjS2YdGQENdxVYhNiOJTjcTJqanPKpqxyFROrQG2K1O-RdwTjAQNsHj1Mv4gXjfLkaqOgsY1aDJCMN2ox3pAIkawUOcGnE0JlzFedc4novHR7my3AUIdah-p3jFn9a_qH_xzlETpoQCbu1lZxjLZsfoL2Bg2NfopMN59n5L331MdmtvgosSoxAEHsOQzsMgCExKNPXDdnLTEAWwxhclZkBj6b23X9atPEibMce2njOpDiz2UxzdQZeuv3Xh-fSSO3QFIm6JwAEHIBt6nPUUKueSTA2QOuAyecNJQLaWN_Pj3nSSwTpR2nOk25s_CcctTQc7STF7m9RDhIHE2s1FRBBuYiJb1qoGOQKlEmmBBthFfTNwFz9hyFgsEvysl6Atvool6CybQ-dmMSJnBTxMHV3y9fo_2a9fG1YDeo5cCV7S3aTb_nWTm7q8wErsPR4AfC5sVS |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Anti-VEGF+drugs+as+the+2009+first-line+therapy+for+choroidal+neovascularization+in+pathologic+myopia&rft.jtitle=Retina+%28Philadelphia%2C+Pa.%29&rft.au=Cohen%2C+Salomon+Y&rft.date=2009-09-01&rft.eissn=1539-2864&rft.volume=29&rft.issue=8&rft.spage=1062&rft_id=info:doi/10.1097%2FIAE.0b013e3181b1bb1a&rft_id=info%3Apmid%2F19734760&rft_id=info%3Apmid%2F19734760&rft.externalDocID=19734760 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1539-2864&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1539-2864&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1539-2864&client=summon |